Theranautilus Secures $1.2 Mn in Seed...
19 Nov 2024
India’s third-largest pharma company, Cipla, reported an 18.27% year-on-year (Y-o-Y) increase in net profit for the first quarter of FY2024-25, reaching ₹1,177.64 crore, surpassing analysts’ expectations. The company’s revenue from operations grew by 5.8% Y-o-Y to ₹6,624.86 crore, driven by strong performances in India and the US.
Sequentially, Cipla saw an 8.6% rise in revenue and a 25.4% increase in profit after tax (PAT). The stock hit an all-time high of ₹1,578 per share, a 5.2% jump from the previous close on BSE.
Cipla’s US business reported a record quarterly revenue of $250 million, thanks to traction in differentiated portfolios and a 17% market share in the respiratory drug Generic Albuterol. The Indian branded prescription business grew by 10%, led by strong performance in chronic therapies such as respiratory, cardiac, and urology, which outperformed the market.
The company completed the transition of its India trade generics business to a new distribution model, which is expected to enhance operational control and distributor reach. The Indian Consumer Health division grew by 3% Y-o-Y, driven by key brands like Nicotex, Omnigel, and Cipladine.
In South Africa, Cipla secured the top position in the private market, recording a 19% Y-o-Y growth in local currency terms, outperforming the overall market significantly.
Cipla is focusing on diversifying its product portfolio, exploring new fields like obesity and mental health, and strengthening its presence in neurology and antimicrobial resistance. The company is also actively pursuing merger and acquisition opportunities in India and select global markets to align with its core expansion areas.
Cipla invested ₹353 crore in research and development (R&D), representing 5.3% of sales, primarily for product filings and developmental initiatives. The company has a net cash balance of ₹8,449 crore, with debt obligations mainly related to lease liabilities and working capital management.
Chat on WhatsApp
Request a call back
